发布求助
文献互助 智能选刊 最新文献

Clinical pharmacology and therapy最新文献

筛选
英文 中文
SGLT-2 inhibitors in chronic kidney disease: state of the art 慢性肾脏疾病中的SGLT-2抑制剂:最新进展
Clinical pharmacology and therapy Pub Date : 2022-09-12 DOI: 10.32756/0869-5490-2022-3-53-58
I. Sabirov, I. Murkamilov, V. Fomin, Z. Murkamilova, A. Sabirova
{"title":"SGLT-2 inhibitors in chronic kidney disease: state of the art","authors":"I. Sabirov, I. Murkamilov, V. Fomin, Z. Murkamilova, A. Sabirova","doi":"10.32756/0869-5490-2022-3-53-58","DOIUrl":"https://doi.org/10.32756/0869-5490-2022-3-53-58","url":null,"abstract":"All patients with chronic kidney disease (CKD) require treatment to reduce the risk of cardiovascular events and to prevent progression of renal failure. ACE inhibitors and angiotensin receptor blockers are widely used for cardio- and nephroprotection in patients with CKD. Sodium glucose cotransporter type 2 (SGLT-2) inhibitors show significant prospects for reducing morbidity and mortality in this population. SGLT-2 inhibitors have been developed for treatment of patients with type 2 diabetes mellitus. However, evidence from multiple randomized clinical trials suggested that these drugs have cardio- and nephroprotective effects in patients with and without diabetes. Despite a wealth of data, SGLT-2 inhibitors remain underused by nephrologists or cardiologists. This is not surprising since new therapies traditionally take decades from research to clinical implementation due to many barriers, including lack of knowledge, concern about drug side effects, lack of decision support, cost, and clinical inertia. The review article presents data from scientific studies on the renoprotective effect of SGLT-2 inhibitors and the mechanisms of this activity in CKD patients.","PeriodicalId":10353,"journal":{"name":"Clinical pharmacology and therapy","volume":"20 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"77686381","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Efficacy and safety of upadacitinib in psoriatic arthritis upadacitinib治疗银屑病关节炎的疗效和安全性
Clinical pharmacology and therapy Pub Date : 2022-09-12 DOI: 10.32756/0869-5490-2022-3-38-46
P. Novikov, N. Bulanov, S. Gulyaev, E. Grunina, E. Kuznetsova, T. Shevtsova, S. Moiseev
{"title":"Efficacy and safety of upadacitinib in psoriatic arthritis","authors":"P. Novikov, N. Bulanov, S. Gulyaev, E. Grunina, E. Kuznetsova, T. Shevtsova, S. Moiseev","doi":"10.32756/0869-5490-2022-3-38-46","DOIUrl":"https://doi.org/10.32756/0869-5490-2022-3-38-46","url":null,"abstract":"Psoratic arthritis (PsA) is a common disorder affecting every fifth patient with psoriasis. Typical clinical manifestations of PsA include asymmetric mono/oligoathritis or polyarthritis, spondyloarthritis, enthesitis and dactylitis. More rarely PsA is associated with uveitis and inflammatory bowel disease. Upadacitinib is a selective JAK-kinase inhibitor approved for treatment of PsA. Its efficacy and favorable safety profile in PsA patients were established in two randomized placebocontrolled phase 3 clinical trials (SELECT-PsA 1 and 2). In both studies, upadacitinib was significantly more effective than placebo and improved activity of PsA, psoriatic lesions, enthesitis and dactylitis. Moreover, upadacitinib is approved for treatment of axial spondylitis and, therefore, can be used in patients with any manifestations of PsA. The authors present clinical cases of PsA and discuss indications for upadacitinib administration in such patients.","PeriodicalId":10353,"journal":{"name":"Clinical pharmacology and therapy","volume":"39 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"88813612","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Heart involvement in Fabry disease: clinical features, cardiac MRI and speckle-tracking echocardiography 法布里病累及心脏:临床特征、心脏MRI和斑点跟踪超声心动图
Clinical pharmacology and therapy Pub Date : 2022-09-12 DOI: 10.32756/0869-5490-2022-3-22-29
A. Moiseev, E. Mershina, A. Safarova, E. Tao, N. Bulanov, V. Sholomova, Z. Kobalava, E. Pavlikova, S. Moiseev, V. Fomin
{"title":"Heart involvement in Fabry disease: clinical features, cardiac MRI and speckle-tracking echocardiography","authors":"A. Moiseev, E. Mershina, A. Safarova, E. Tao, N. Bulanov, V. Sholomova, Z. Kobalava, E. Pavlikova, S. Moiseev, V. Fomin","doi":"10.32756/0869-5490-2022-3-22-29","DOIUrl":"https://doi.org/10.32756/0869-5490-2022-3-22-29","url":null,"abstract":"To evaluate the frequency and clinical features of heart involvement in Fabry disease (FD) and diagnostic value of cardiac MRI and speckle-tracking echocardiography.","PeriodicalId":10353,"journal":{"name":"Clinical pharmacology and therapy","volume":"322 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"80273676","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
The socioeconomic burden of paracetamol adverse reactions over 10 years in Russia 俄罗斯10年来扑热息痛不良反应的社会经济负担
Clinical pharmacology and therapy Pub Date : 2022-09-12 DOI: 10.32756/0869-5490-2022-3-60-66
G.I. Sirayeva, A. Kolbin, A. Kalyapin, Y. Balykina
{"title":"The socioeconomic burden of paracetamol adverse reactions over 10 years in Russia","authors":"G.I. Sirayeva, A. Kolbin, A. Kalyapin, Y. Balykina","doi":"10.32756/0869-5490-2022-3-60-66","DOIUrl":"https://doi.org/10.32756/0869-5490-2022-3-60-66","url":null,"abstract":"To evaluate the socioeconomic burden of paracetamol adverse reactions.","PeriodicalId":10353,"journal":{"name":"Clinical pharmacology and therapy","volume":"18 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"82783605","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Pharmaceutical care for patients with headache: a systematic review of clinical studies 头痛患者的药物治疗:临床研究的系统回顾
Clinical pharmacology and therapy Pub Date : 2022-09-12 DOI: 10.32756/0869-5490-2022-3-47-52
O. Reshetko, A. I. Grishin
{"title":"Pharmaceutical care for patients with headache: a systematic review of clinical studies","authors":"O. Reshetko, A. I. Grishin","doi":"10.32756/0869-5490-2022-3-47-52","DOIUrl":"https://doi.org/10.32756/0869-5490-2022-3-47-52","url":null,"abstract":"The article presents an overview of studies of pharmaceutical care for patients with different types of headache. Various methods were used, including education of pharmacists, questionnaires for patients and specialists, interviews, the use of special protocols and algorithms for providing pharmaceutical care, patient modelling.","PeriodicalId":10353,"journal":{"name":"Clinical pharmacology and therapy","volume":"4 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"73273665","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Classic homocystinuria: etiology, natural history and treatment 经典同型半胱氨酸尿:病因、自然病史及治疗
Clinical pharmacology and therapy Pub Date : 2022-09-12 DOI: 10.32756/0869-5490-2022-3-30-37
S. Moiseev, N. Chebotareva, N. Bulanov, P. Novikov, E. Shchegoleva, T. Shevtsova, E. Tao, E. Filatova
{"title":"Classic homocystinuria: etiology, natural history and treatment","authors":"S. Moiseev, N. Chebotareva, N. Bulanov, P. Novikov, E. Shchegoleva, T. Shevtsova, E. Tao, E. Filatova","doi":"10.32756/0869-5490-2022-3-30-37","DOIUrl":"https://doi.org/10.32756/0869-5490-2022-3-30-37","url":null,"abstract":"Classic homocystinuria is a rare autosomal recessive disorder of methionine metabolism resulting from a deificiency of cystathionine beta-synthase that is involved in transsulfuration of homocysteine. The disorder is caused by mutations of CBS gene. Lack of enzyme is associated with accumulation of homocysteine that induce various toxicities, e.g. endothelial dysfunction and increased risk of thrombosis. Clinical manifestations of classic homocystinuria include ectopia lentis and/or severe myopia, skeletal abnormalities (marfanoid habitus, generalized osteoporosis and bone deformity), mental retardation, seizures, psychiatric and behavioral disorderts, venous and arterial thrombosis. Some patients with milder form of the disease can present only with thromboembolic events in adulthood. Diagnosis of classic homocystinuria should by established by biochemical (elevated plasma homocysteine and methionine and low cistathione) and genetic (homozygous and compound heterozygous mutations of CBS gene) tests. Low methionine diet, vitamin B6, folic acid and betaine anhydrous, a methylating agent, can be used to reduce homocysteine levels, to prevent progression of the homocystinuria and thromboembolic events.","PeriodicalId":10353,"journal":{"name":"Clinical pharmacology and therapy","volume":"52 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"79821381","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cardio- and nephroprotective effects of antihypertensive therapy in nonadherent hypertensive patients 抗高血压治疗对非依从性高血压患者的心脏和肾保护作用
Clinical pharmacology and therapy Pub Date : 2022-09-12 DOI: 10.32756/0869-5490-2022-3-16-21
S. Simenyura, Z. Sizova, N. N. Shindryaeva, A.V. Legoshina
{"title":"Cardio- and nephroprotective effects of antihypertensive therapy in nonadherent hypertensive patients","authors":"S. Simenyura, Z. Sizova, N. N. Shindryaeva, A.V. Legoshina","doi":"10.32756/0869-5490-2022-3-16-21","DOIUrl":"https://doi.org/10.32756/0869-5490-2022-3-16-21","url":null,"abstract":"To evaluate the impact of various regimens of antihypertensive treatment on blood pressure and target organs in nonadherent hypertensive patients.","PeriodicalId":10353,"journal":{"name":"Clinical pharmacology and therapy","volume":"30 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"81302526","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Comparative efficacy of olokizumab and tocilizumab in hospitalized patients with COVID-19 olokizumab与tocilizumab在COVID-19住院患者中的比较疗效
Clinical pharmacology and therapy Pub Date : 2022-09-12 DOI: 10.32756/0869-5490-2022-3-9-15
M. Brovko, P. Novikov, E. Nabatchikova, N. Bulanov, E. Tao, P. Potapov, L. Akulkina, N. Soloveva, S. Moiseev
{"title":"Comparative efficacy of olokizumab and tocilizumab in hospitalized patients with COVID-19","authors":"M. Brovko, P. Novikov, E. Nabatchikova, N. Bulanov, E. Tao, P. Potapov, L. Akulkina, N. Soloveva, S. Moiseev","doi":"10.32756/0869-5490-2022-3-9-15","DOIUrl":"https://doi.org/10.32756/0869-5490-2022-3-9-15","url":null,"abstract":"To compare the efficacy of olokizumab and tocilizumab in reducing the risk of invasive mechanical ventilation or death in hospitalized patients with COVID-19.","PeriodicalId":10353,"journal":{"name":"Clinical pharmacology and therapy","volume":"79 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"86833984","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Venous congestion on the VExUS scale in patients with decompensated heart failure 失代偿性心力衰竭患者的静脉充血
Clinical pharmacology and therapy Pub Date : 2022-06-04 DOI: 10.32756/0869-5490-2022-2-27-31
R. Aslanova, Z. Kobalava, A. Safarova, M. Vatsik-Gorodetskaya, V. Efimova, E. Cabello Montoya Flora, A. O. Kurlaeva, A. Abramov
{"title":"Venous congestion on the VExUS scale in patients with decompensated heart failure","authors":"R. Aslanova, Z. Kobalava, A. Safarova, M. Vatsik-Gorodetskaya, V. Efimova, E. Cabello Montoya Flora, A. O. Kurlaeva, A. Abramov","doi":"10.32756/0869-5490-2022-2-27-31","DOIUrl":"https://doi.org/10.32756/0869-5490-2022-2-27-31","url":null,"abstract":"Persistent venous congestion in patients with decompensated heart failure (DCHF) increases the risk of rehospitalization and death. VExUS protocol that evaluates the systemic hepatic-renal congestion in addition to assessing the inferior vena cava is regarded as a promising non-invasive ultrasound method to assess venous congestion in these patients.","PeriodicalId":10353,"journal":{"name":"Clinical pharmacology and therapy","volume":"17 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-06-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"86783930","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Clinical and pharmacological features and place of irbesartan in the treatment of cardiovascular diseases 厄贝沙坦治疗心血管疾病的临床、药理特点及地位
Clinical pharmacology and therapy Pub Date : 2022-06-04 DOI: 10.32756/0869-5490-2022-2-57-62
E. V. Rebrova, E. Shikh, A.Yu. Ryazanovа
{"title":"Clinical and pharmacological features and place of irbesartan in the treatment of cardiovascular diseases","authors":"E. V. Rebrova, E. Shikh, A.Yu. Ryazanovа","doi":"10.32756/0869-5490-2022-2-57-62","DOIUrl":"https://doi.org/10.32756/0869-5490-2022-2-57-62","url":null,"abstract":"Irbesartan belongs to a group of angiotensin II receptor blockers that are used worldwide for the treatment of patients with hypertension, type 2 diabetes, and impaired renal function. Irbesartan can be administered alone or in combination with other antihypertensive drugs (for example, hydrochlorothiazide), if blood pressure control cannot be achieved with monotherapy. The mechanism of action of Irbesartan is mainly due to the selective blockade of AT1 receptors and, as a consequence, a decrease in the vasopressor effect of angiotensin II. The review article summarizes pharmacokinetic and pharmacodynamic properties and clinical data on the tolerability and safety of Irbesartan.","PeriodicalId":10353,"journal":{"name":"Clinical pharmacology and therapy","volume":"261 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-06-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"75769547","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信